Redirecting Immune, Lipid and Metabolic Drivers of Early Cardiovascular Disease: The RESET Cohort Study
Recruiting · NCT06211868 · Observational (researchers observe without assigning treatment) · Lead sponsor: National University Hospital, Singapore
View the official record on ClinicalTrials.gov →Interventions studied
Digital wearable and AI-human symbiotic lifestyle intervention
What this trial is about
Project RESET is a Singapore National Medical Research Council Large Collaborative Grant funded program that brings together a nationwide community of cardiovascular, metabolic, and digital health researchers, as well as clinicians across primary and tertiary care to study the immune, lipid and metabolic drivers of early cardiovascular disease. RESET incorporates a nested randomised controlled trials (RCT) to test the use of a combined digital wearable and AI-human symbiotic lifestyle intervention to halt or reverse the progression of early disease.
Who can take part
Age range
40 Years to 70 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- 40-70 years old
- ASCVD (atherosclerotic cardiovascular disease) score of 5% and higher
Exclusion criteria
- Previous major cardiovascular disease (myocardial infarction, heart failure, ischemic stroke)
- Limited life expectancy
- Other ongoing unstable medical conditions
- Pregnant women
Where it is running
1 location listed.
- NUS - Singapore, Singapore